The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis

Best Practice and Research: Clinical Rheumatology

Volumn 26, Issue 5, 2012, Pages 659-676

  Tsao, Nicole W ^a   Bansback, Nick J ^a,b   Shojania, Kam ^a   Marra, Carlo A ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

Cost effectiveness; Cost utility analysis; Disease modifying anti rheumatic drugs; Economic evaluation; Rheumatoid arthritis; TNF alpha inhibitors

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL RESPONSE MODIFIER; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE ACTIVITY; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; NORTH AMERICA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; HUMANS; IMMUNOCONJUGATES; NORTH AMERICA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870501644     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2012.07.012     Document Type: Review

References (67)

1. S.E. Gabriel, and K. Michaud Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases Arthritis Research and Therapy 11 3 2009 229
2. Canadian Agency for Drugs and Technologies in Health Clinical and economic overview: biological response modifier agents for adults with rheumatoid arthritis 2010 Jul CADTH
3. V.P. Bykerk, P. Akhavan, G.S. Hazlewood, O. Schieir, A. Dooley, and B. Haraoui Canadian rheumatology association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs The Journal of Rheumatology 39 8 2011 Sep 15 1559 1582
4. A. Boonen, and J.L. Severens The burden of illness of rheumatoid arthritis Clinical Rheumatology 30 Suppl. 1 2011 Mar S3 S8
5. D.M. Lee, and M.E. Weinblatt Rheumatoid arthritis Lancet 358 9285 2001 Sep 15 903 911
6. E. Badley, I. Rasooly, and G. Webster Relative importance of musculoskeletal disorders as a cause of chronic health problems, disability, and health care utilization: findings from the 1990 Ontario health survey The Journal of Rheumatology 21 3 1994 Mar 505 514
7. P. Emery Evidence supporting the benefit of early intervention in rheumatoid arthritis The Journal of Rheumatology Supplement 66 Supplement 2002 Nov 3 8
8. S.K. Agarwal Biologic agents in rheumatoid arthritis: an update for managed care professionals Journal of Managed Care Pharmacy 17 9 2011 14
9. L. Klareskog, A.I. Catrina, and S. Paget Rheumatoid arthritis Lancet 373 9664 2009 Feb 21 659 672
10. J.A. Singh, R. Christensen, G.A. Wells, M.E. Suarez-Almazor, R. Buchbinder, and M.A. Lopez-Olivo Biologics for rheumatoid arthritis: an overview of cochrane reviews Cochrane Database System Reviews 4 2009 CD007848
11. R. Fleischmann, M. Cutolo, M.C. Genovese, E.B. Lee, K.S. Kanik, and S. Sadis Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs Arthritis and Rheumatism 64 3 2012 Mar 617 629
12. J.M. Kremer, S. Cohen, B.E. Wilkinson, C.A. Connell, J.L. French, and J. Gomez-Reino A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone Arthritis and Rheumatism 64 4 2012 Apr 970 981
13. J. Kremer, Z.G. Li, S. Hall, R. Fleischmann, and M. Genovese Tofacitinib (CP-690,550), an oral JAK inhibitor, in combination with traditional DMARDS: phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDS Annals of the Rheumatic Diseases 70 Supple3 2011 170
14. M. Drummond, M. Schulpher, G. Torrance, B. O'Brien, and G. Stoddart Methods for the economic evaluation of health care programmes 3rd ed. 2005 Oxford University Press New York, NY
15. Organisation for Economic Cooperation and Development PPPs and exchange rates [Internet] [cited 2012 Aug 1]. Available from: 2012 http://stats.oecd.org/ Index.aspx?DataSetCode=SNA-TABLE4#
16. Statistics Canada, Government of Canada. Consumer price index, health and personal care, by province (monthly) [Internet]. [cited 2012 Jul 29]. Available from: http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/cpis13a-eng. htm.
17. Statistics Canada, Government of Canada The consumer price index: table 7 - the consumer price index for Canada, major components and special aggregates, not seasonally adjusted, historical data [Internet] 2012 [cited 2012 Jul 29]. Available from: http://www.statcan.gc.ca/pub/62-001-x/2012003/t041-eng.htm
18. Y. Chen, P. Jobanputra, P. Barton, S. Jowett, S. Bryan, and W. Clark Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis Health Technology Assessment 10 42 2006 Nov
19. J.R. Spalding, and J. Hay Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis Pharmacoeconomics 24 12 2006 1221 1232
20. W.B. van den Hout, Y.P.M. Goekoop-Ruiterman, C.F. Allaart, J.K. de Vries-Bouwstra, J.M.M. Hazes, and P.J.S.M. Kerstens Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis Arthritis and Rheumatism 61 3 2009 Mar 15 291 299
21. A. Finckh, N. Bansback, C.A. Marra, A.H. Anis, K. Michaud, and S. Lubin Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis Annals of Internal Medicine 151 9 2009 Nov 3 612 621
22. A. Davies, M.A. Cifaldi, O.G. Segurado, and M.H. Weisman Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis The Journal of Rheumatology 36 1 2009 Jan 16 26
23. L.G. Schipper, W. Kievit, A.A. den Broeder, M.A. van der Laar, E.M.M. Adang, and J. Fransen Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective Rheumatology 50 7 2011 Jul 1 1320 1330
24. G. Kobelt, I. Lekander, A. Lang, B. Raffeiner, C. Botsios, and P. Geborek Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment International Journal of Technology Assessment Health Care 27 3 2011 Jul 193 200
25. H.K. Choi, J.D. Seeger, and K.M. Kuntz A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis Arthritis and Rheumatism 43 10 2000 Oct 2316 2327
26. Coyle D, Judd M, Blumenhauer B, Cranney A, Maetzel A, Tugwell P, et al. Infliximab and etanercept in patients with rheumatoid arthritis: a systematic review and economic evaluation. Ottawa, ON: Canadian Coordinating Office for Health Technology Assessment; 2006. Report No.: 64.
27. A. Russell, A. Beresniak, L. Bessette, B. Haraoui, P. Rahman, and C. Thorne Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis Clinical Rheumatology 28 4 2009 Apr 403 412
28. D.T. Felson, J.J. Anderson, M. Boers, C. Bombardier, D. Furst, C. Goldsmith American College of Rheumatology Preliminary definition of improvement in rheumatoid arthritis Arthritis and Rheumatism 38 6 1995 Jun 727 735
29. Moreland L, O'Dell J, Paulus H, Curtis J, Bathon J, St. Clair E, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early, aggressive rheumatoid arthritis. Arthritis and Rheumatism. Accepted Article.
30. J.B. Wong, G. Singh, and A. Kavanaugh Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis American Journal of Medicine 113 5 2002 Oct 1 400 408
31. P. Jobanputra, P. Barton, S. Bryan, and A. Burls The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation Health Technology Assessment 6 21 2002 Sep
32. G. Kobelt, L. Jönsson, A. Young, and K. Eberhardt The cost-effectiveness of infliximab (remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study Rheumatology (Oxford) 42 2 2003 Feb 326 335
33. P. Barton, P. Jobanputra, J. Wilson, S. Bryan, and A. Burls The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis Health Technology Assessment 8 11 2004 Mar 1 91 iii
34. A. Brennan, N. Bansback, A. Reynolds, and P. Conway Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK Rheumatology (Oxford) 43 1 2004 Jan 62 72
35. P.M.J. Welsing, J.L. Severens, M. Hartman, P.L.C.M. van Riel, and R.F.J.M. Laan Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands Arthritis and Rheumatism 51 6 2004 Dec 15 964 973
36. M. Barbieri, J.B. Wong, and M. Drummond The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK Pharmacoeconomics 23 6 2005 607 618
37. G. Kobelt, P. Lindgren, A. Singh, and L. Klareskog Cost effectiveness of etanercept (enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial Annals of the Rheumatic Diseases 64 8 2005 Aug 1174 1179
38. N.J. Bansback, A. Brennan, and O. Ghatnekar Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden Annals of the Rheumatic Diseases 64 7 2005 Jul 995 1002
39. M. Tanno, I. Nakamura, K. Ito, H. Tanaka, H. Ohta, and M. Kobayashi Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis Modern Rheumatology 16 2 2006 77 84
40. A. Brennan, N. Bansback, R. Nixon, J. Madan, M. Harrison, and K. Watson Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British society for rheumatology biologics registry Rheumatology (Oxford) 46 8 2007 Aug 1345 1354
41. C.A. Marra, S.A. Marion, D.P. Guh, M. Najafzadeh, F. Wolfe, and J.M. Esdaile Not all "quality-adjusted life years" are equal Journal of Clinical Epidemiology 60 6 2007 Jun 616 624
42. M. Vera-Llonch, E. Massarotti, F. Wolfe, N. Shadick, R. Westhovens, and O. Sofrygin Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists The Journal of Rheumatology 35 9 2008 Sep 1745 1753
43. A.J. Wailoo, N. Bansback, A. Brennan, K. Michaud, R.M. Nixon, and F. Wolfe Biologic drugs for rheumatoid arthritis in the medicare program: a cost-effectiveness analysis Arthritis and Rheumatism 58 4 2008 Apr 939 946
44. I. Lekander, F. Borgström, P. Svarvar, T. Ljung, C. Carli, and R.F. van Vollenhoven Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden International Journal of Technology Assessment Health Care 26 1 2010 Jan 54 61
45. C.M. Nguyen, M. Bounthavong, M.A.S. Mendes, M.L.D. Christopher, J.N. Tran, and R. Kazerooni Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis Pharmacoeconomics 30 7 2012 Jul 575 593
46. E.J. Soini, T.A. Hallinen, K. Puolakka, V. Vihervaara, and M.J. Kauppi Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis Journal of Medical Economics 15 2 2012 340 351
47. A. Diamantopoulos, M. Benucci, S. Capri, W. Berger, N. Wintfeld, and G. Giuliani Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy Journal of Medical Economics 15 3 2012 576 585
48. A. Saraux, L. Gossec, P. Goupille, B. Bregman, E. Boccard, and D. Dupont Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France Rheumatology (Oxford) 49 4 2010 Apr 733 740
49. A. Beresniak, R. Ariza-Ariza, J.F. Garcia-Llorente, A. Ramirez-Arellano, and D. Dupont Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain International Journal of Inflammation 2011 2011 1 9
50. M.A. Cimmino, G. Leardini, F. Salaffi, M. Intorcia, A. Bellatreccia, and D. Dupont Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach Clinical and Experimental Rheumatology 29 4 2011 Aug 633 641
51. K. Puolakka, H. Blåfield, M. Kauppi, R. Luosujärvi, R. Peltomaa, and T. Leikola-Pelho Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland Open Rheumatology Journal 6 2012 38 43
52. A. Kielhorn, D. Porter, A. Diamantopoulos, and G. Lewis UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug Current Medical Research and Opinion 24 9 2008 Sep 2639 2650
53. S. Merkesdal, T. Kirchhoff, D. Wolka, G. Ladinek, A. Kielhorn, and A. Rubbert-Roth Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure European Journal of Health Economics 11 1 2010 Feb 95 104
54. T.A. Hallinen, E.J.O. Soini, K. Eklund, and K. Puolakka Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting Rheumatology (Oxford) 49 4 2010 Apr 767 777
55. Y. Yuan, D. Trivedi, R. Maclean, and L. Rosenblatt Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States Journal of Medical Economics 13 1 2010 Mar 33 41
56. K. Malottki, P. Barton, A. Tsourapas, A.O. Uthman, Z. Liu, and K. Routh Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation Health Technology Assessment 15 14 2011
57. P. Lindgren, P. Geborek, and G. Kobelt Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden International Journal of Technology Assessment in Health Care 25 02 2009 Mar 31 181
58. ® in the treatment of rheumatoid arthritis in Spain Reumatología Clínica 6 4 2010 Aug 203 211
59. J. Braun, P. Kästner, P. Flaxenberg, J. Währisch, P. Hanke, and W. Demary Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial Arthritis and Rheumatism 58 1 2008 Jan 73 81
60. C. Gabay, P. Emery, R. van Vollenhoven, A. Dikranian, R. Alten, and M. Klearman Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 ADACTA trial Annals of the Rheumatic Diseases 71 Suppl. 3 2012 152
61. P. Barton, S. Bryan, and S. Robinson Modelling in the economic evaluation of health care: selecting the appropriate approach Journal of Health Services Research and Policy 9 2 2004 Apr 110 118
62. B. O'Brien Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials? Medical Care 34 12 Suppl. 1996 Dec DS99 108
63. Y.P.M. Goekoop-Ruiterman, J.K. de Vries-Bouwstra, C.F. Allaart, D. van Zeben, P.J.S.M. Kerstens, and J.M.W. Hazes Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial Arthritis and Rheumatism 58 2 Suppl. 2008 Feb S126 S135
64. G. van der Velde, B. Pham, M. Machado, L. Ieraci, W. Witteman, and C. Bombardier Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review Arthritis Care and Research (Hoboken) 63 1 2011 Jan 65 78
65. B. Fautrel, S.M.M. Verstappen, and A. Boonen Economic consequences and potential benefits Best Practice and Research Clinical Rheumatology 25 4 2011 Aug 607 624
66. H.K. Choi, J.D. Seeger, and K.M. Kuntz A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis The Journal of Rheumatology 29 6 2002 Jun 1156 1165
67. M. Vera-Llonch, E. Massarotti, F. Wolfe, N. Shadick, R. Westhovens, and O. Sofrygin Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate Rheumatology 47 4 2008 Apr 1 535 541